

EBR's SOLVE-CRT trial data accepted into HRS conference

Sunnyvale, California; 21 March 2023: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing system for heart failure, is pleased to announce the acceptance of its pivotal SOLVE-CRT (“SOLVE”) trial abstract at Heart Rhythm 2023, being held in New Orleans, US from 19 to 21 May 2023.

Heart Rhythm 2023 is the Heart Rhythm Society’s (HRS) annual meeting and is the largest gathering of heart rhythm professionals globally. The inclusion of this abstract in the premier global electrophysiology conference underpins the importance of EBR’s SOLVE study within the cardiovascular field, with the aim to materially improve patient outcomes.

The abstract presentation, titled “*Safety and Efficacy of a Leadless Ultrasound-Based Cardiac Resynchronization Pacing System in Heart Failure – Results from the SOLVE-CRT Study*” will be presented by Dr. Jagmeet P. Singh MD DPhil (Co-Principal Investigator) on behalf of Dr Mary Norine Walsh MD MACC (Co-Principal Investigator) and the other SOLVE investigators on 21 May 2023 (22 May 2023 AEST). Details of the presentation are as follows:

Session title: LB-456088 Late Breaking Clinical Trials and Science

Session details: 21 May 2023 from 09:30 to 10:30am US CDT

The abstract was submitted without any outcomes as the data is still being analysed. Acceptance of this abstract for presentation at Heart Rhythm 2023 requires an embargo on all SOLVE clinical data until 06:00am EDT the day of the abstract presentation. EBR expects to make an announcement on the data and hold a webinar to discuss the data and results, on Monday, 22 May 2023 (AEST).

John McCutcheon, President and CEO of EBR Systems said:

“We are honoured to be accepted into such a prestigious conference and to have our results featured in the Late Breaking Clinical Trials session. These sessions get the most recognition in the clinical community. A positive trial outcome, if achieved, would represent a significant milestone on our path towards achieving FDA and regulatory approvals, whereby we can commence our commercialisation strategy.”

ENDS

This announcement has been authorised for release by EBR Systems General Disclosure Committee.

For more information, please contact:

Company

Frank Hettmann
Chief Financial Officer
P: +1 408 720 1906
E: info@ebrsystemsinc.com

Investors

Dean Dribbin
Vesparum Capital
P: +61 3 8582 4800
E: EBRSystems@vesparum.com

About EBR Systems (ASX: EBR)

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

EBR Systems' WiSE® Technology

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Given the current uncertainties regarding the impact of the COVID-19 on the trading conditions impacting the Company, the financial markets and the health services world-wide, investors are cautioned not to place undue reliance on the current trading outlook.

EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

Foreign Ownership Restriction

EBR's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.